Iovance_Biotherapeutics

Iovance Biotherapeutics

Iovance Biotherapeutics

American biopharmaceutical startup

Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.[1][2]

Quick Facts Formerly, Company type ...

History

The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became lion bio Pharma, then rebranded to Iovance in 2017.[3]

In 2024 the US FDA gave accelerated approval to Lifileucel, the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma.[4]

See also

References

  1. [1]
    Garber, Ken (7 August 2019). "Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up". Nature Biotechnology. Retrieved 14 August 2019.
  2. [2]
    Adelman, Jacob (29 May 2019). "New Navy Yard lab and office complex planned for Calif. cell-therapy research firm Iovance". The Philadelphia Inquirer. Retrieved 14 August 2019.
  3. [3]
    "Genesis Biopharma Announces Completion of Merger with Lion Biotechnologies". www.businesswire.com. 2013-07-25. Retrieved 2020-01-17.
  4. [4]
    Mullard, Asher (2024-02-19). "FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers". Nature Reviews Drug Discovery. doi:10.1038/d41573-024-00035-1. PMID 38374249.
  • Official website
  • Business data for Iovance Biotherapeutics, Inc.:
Stub icon

This United States corporation or company article is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Iovance_Biotherapeutics, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.